Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
暂无分享，去创建一个
M. Piccart | M. Rozencweig | P. Dodion | N. Crespeigne | C. Nicaise | D. Kisner | Y. Kenis | E. Cumps
[1] V. Devita,et al. Animal toxicology for early clinical trials with anticancer agents. , 1981, Cancer clinical trials.
[2] R. Verwilghen,et al. Drug Dependent Red Cell Antibodies and Intravascular Haemolysis Occurring in Patients Treated with 9 Hydroxy‐Methyl‐Ellipticinium , 1980, British journal of haematology.
[3] C. Paoletti,et al. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers. , 1978, European journal of cancer.